The technical bull case for $IBRX
Posted: May 03, 2024
- ANKTIVA, a new drug approved by the FDA for bladder cancer treatment, is a big deal both technically and financially - Current cancer treatments include surgery, chemotherapy, radiation, and immunotherapy - Immunotherapy drugs like Bacillus Calmette-Guerin (BCG) have been effective in bladder cancer treatment but have limitations - ANKTIVA in combination with BCG shows promising results in clinical trials for bladder cancer treatment - ANKTIVA is also in Phase 2 trials for lung cancer, colon cancer, and other forms of cancer - Immunity Bio, the company behind ANKTIVA, had sales revenue of $0.6 million in 2023, with potential revenue projections ranging from $50 million to $900 million once ANKTIVA is fully available - Release of ANKTIVA expected in the US by mid-May - Serum Institute of India to provide exclusive supply of BCG for ANKTIVA treatment - Executive Chairman of Immunity Bio to discuss ANKTIVA approval at American Urological Association conference - Speculative investment position: 10 Call Contracts for IBRX with a strike price of $5 and expiry on 12/19/2025
Summarized top reddit comments: - Detailed DD on $IBRX with positive outlook - Mention of CEO's successful track record - Potential for high target price in near future - Caution about mentioning stock on certain forums - Confidence in investment with calls and shares - Emphasis on groundbreaking nature of new treatment - Willingness to invest without reading full post
Stay ahead of the market with AI stock alerts & AI summaries of the latest earnings, stock ideas for free with Fluid Bot. Sign up now!